Showing 1213 results
- Media Release /FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
- Media Release /After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…
- Media Release /Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
- Media Release /Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
- Key Release /Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
- Media Release /Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
- Media Release /Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
- Media Release /New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
- Media Release /Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
- Media Release /For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…